Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive Function and Mobility in Pain
NCT02974114Phase 4Terminated
- Sponsor
- GSK
- Start
- Oct 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of paracetamol + caffeine in acute pain (3 arms), sponsored by GSK. Primary endpoints: Change From Pain Free State (Day 3) in Error Adjusted Simple Reaction Time (SRT) in the Pain State (Day 2), Change From Pain-free State (Day 3) in Reaction Time in the Pain State (Day 2) and 4 more. Started Oct 2016; status: terminated.
02
Drugs
paracetamol + caffeine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT02974114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974114.